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Oral Presentations S175Results: Eleven inpatient HSCT recipients were diagnosed with
probable/proven H1N1 influenza in our two centers. Ten had un-
dergone allogeneic HSCT and one had undergone autologous
HSCT. Eight of the 10 allogeneic recipients had either active or
prior GVHD, and 6 were on./5 20 mg of prednisone. The diagno-
sis of S-OIV was made 12 -1000 (median 355) days after HSCT.
Three patients had suspected noscomial infection. Clinical presenta-
tions were diverse, ranging from atypical (febrile/neutropenia with-
out respiratory tract symptoms) to mild (low grade fever and mild
cough) to classic influenza symptoms (high fever, chills, sore throat,
myalgias, cough, headache and nasal congestion). Severity of pre-
senting symptoms did not correlate with outcome; however, hypox-
emia and lower tract disease at diagnosis were predictive of poor
outcomeTwo of 8 rapid tests, 7 of 9 cultures, and 7 of 7 PCR samples
sent were positive for influenza A. Ten patients were treated with an-
tivirals (oseltamivir in 10, + rimantidine in 3). Three patients died
(27%) of progressive pneumonia. Of the two who received antivirals
before death, duration from symptom onset to treatment was a me-
dian of 7.5 days (range 2-15), compared with 7 days (range 1-15) in
those who survived.
Conclusions: S-OIV is a cause of significant morbidity and mor-
tality in HSCT recipients. Patients with cGVHD may be particu-
larly susceptible. Clinical presentation may be subtle and a high
state of vigilance is warranted. The sensitivity of the rapid influenza
test is low. Treatment decisions should be focused on disease risk
and clinical symptoms with confirmation by culture or PCR. Pa-
tients presenting with hypoxemia appeared to have worse out-
comes, and early treatment with antivirals may not abrogate the
severity of disease. Finally, nosocomial infection is a risk, demon-
strating the critical need for rigorous enforcement of infection con-
trol policies.56
CMV-SPECIFIC IMMUNITY AND CMV COMPLICATIONS IN SEROPOSITIVE
HCT RECIPIENTS DEPEND ON DONOR SEROSTATUS
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CanadaComparison of D1R1 and D-R1 patients
Anti-CMV T-cell count
D1 R1
n5 46
D-R1
n5 31 P value
CMV-specific CD4 T cells
per ml (median) Day 28
1.50 0.10 0.048*
Day 56 5.23 0.56 0.005*
Day 84 8.19 1.27 0.001*
Day 180 6.26 0.32 0.002*
Pp65-specific CD8 T cells
per ml (median) Day 28
0.81 0.03 0.04*
Day 56 12.16 1.49 0.03*
Day 84 11.26 2.77 0.11*
Day 180 3.87 2.67 0.60*
Clinical Outcomes D1 R1
n5 177
D-R1
n5 121
P value
CMV reactivation above
threshold for preemptive therapy
(No. of patients with at least one
reactivation, (%))
36 (20.3%) 58 (48.7%) 0.001**
Recurrent CMV reactivation
(No. of patients with at least 2
reactivations, (%))
7 (3.9%) 19 (15.9%) 0.003**
CMV disease (No. of patients, (%)) 5 (2.8%) 16(13.3%) 0.005**
Death 74 (41.8%) 68 (56.2%) 0.038**
* Univariate analysis (Mann-Whitney-Wilcoxon rank-sum test) ** Multi-
variate analysis (Binomial linear model) including the following covari-
ates: HLA-matched sibling graft, significant graft versus host disease
(GVHD) (grade 2-4 acute or extensive chronic GVHD), disease stage,
donor age, length of follow-up.Background: Anti-CMV T-cells are thought to control CMV. In
seropositive recipients of grafts from seropositive donors (D + R+),
both naı¨ve and memory/effector anti-CMV T-cells are transferred
with the graft. In seropositive recipients of grafts from seronegative
donors (D-R+), only naı¨ve anti-CMVT-cells are transferredwith the
graft. We hypothesized that counts of anti-CMV T-cells are higher
in the D +R+ compared to the D-R+ group, and that this leads to
a lower incidence of CMV complications like CMV disease or
CMV reactivation.
Patients and methods: We reviewed charts of 298 seropositive re-
cipients for CMV reactivation (pp65 antigenemia or CMV DNAe-
mia above institutional threshold for starting preemptive therapy),
recurrent CMV reactivation (above the same threshold), CMV dis-
ease, and death due to any cause. In 77 of these patients, we deter-
mined the counts of anti-CMV effector T-cells (producing INFg
upon 18 h stimulation with CMV lysate in case of CD4 T-cells or
pp65 overlapping peptides in case of CD8 T-cells). Conditioning
of all patients included rabbit-anti-human thymocyte globulin
(Thymoglobulin).
Results: The anti-CMV T cell, in particular, CD4 T-cell counts
were higher, and the cumulative incidences of CMV reactivation, re-
current CMV reactivation, CMV disease and death were lower in
D + R+ compared to D-R+ patients.
Conclusion: Compared to D + R+ patients, D-R+ have lower
counts of anti-CMV T-cells. This appears to translate into a higher
risk of CMV reactivation, CMV disease and lower survival. New
strategies to avoid CMV complications need to be explored for
D-R+ patients, eg, donor vaccination pre-transplant or infusion of
anti-CMV T-cells post-transplant.LATE EFFECTS/QUALITY OF LIFE
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(HCT): A REPORT FROM THE BONE MARROW TRANSPLANT SURVIVOR
STUDY (BMTSS)
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Forman, S.J.1, Bhatia, S.1 1City of Hope National Medical Center, CA;
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Background: Patients undergoing HCT are at increased of risk
chronic health conditions, including second malignant neoplasms
and cardiovascular disease. Little is known about health behaviors
and cancer screening practices among HCT survivors that could
moderate the risk of these conditions.
Methods: The BMTSS examined health behaviors and cancer
screening practices in individuals who underwent HCT at City of
Hope or University of Minnesota between 1976 and 1998, and sur-
vived 2+ years. Responses from a mailed questionnaire were com-
pared to those obtained from sibling controls. Health behavior was
deemed high-risk if an individual was a current smoker or if they re-
ported risky alcohol intake ($4 drinks/day [males], $3 drinks/day
[females]) on days of alcohol consumption. Questions regarding can-
cer screening practices were tailored to assess adherence to American
Cancer Society guidelines for breast and cervical (females) and testic-
ular (males) cancers.
Results: The study included 1040 survivors: 42.7% underwent al-
logeneic HCT; 43.8% were female; median time from HCT was
7.4 years (range 2.0-27.7 years). Median age at study participation
was 43.8 years (range 18.3-73.0 years) for survivors and 45.2 years
(range 19.3-78.8 years) for siblings (N5 309). Survivors reported
significantly lower rates of high-risk behavior (14.6% v 21.0%;
p\0.01) compared to controls. Adjustment for patient demo-
graphics, SES, diagnosis, HCT-related exposures, and presence
of chronic medical conditions, revealed younger age (\35 years)
at study participation (Odds Ratio [OR]5 5.0; p\0.01), being un-
insured (OR 2.0; p5 0.02), and lower education (\college:
OR5 2.3; p\0.01) to be significantly associated with high-risk be-
havior. HCT survivors reported similar cancer screening practices
when compared to gender-matched sibling controls: Females–
regular self-breast examination (28.9% v 27.0%; p5 0.6), clinical
breast examination (88.4% v 91.3%; p5 0.3), pap smears (85.5%
S176 Oral Presentationsv 89.3%; p5 0.2), and history of one or more mammograms
(93.5% v 91.7%; p5 0.51); Males–regular testicular cancer screen-
ing (17.6% v 20.4; p5 0.5) in the past 2 years.
Conclusions: HCT-survivors had similar cancer screening prac-
tices when compared to healthy sibling controls. The current study
found that despite potential long-term risks, survivors continue to en-
gage in high-risk behaviors such as smoking and excessive alcohol in-
take, indicating the need for targeted interventions in the high-risk
populations.58
PREGNANCY AFTER HEMATOPOIETIC-CELL TRANSPLANTATION: A RE-
PORT FROM THE LATE EFFECTS COMMITTEE OF THE CENTER FOR IN-
TERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH
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Socie, G.10, Rizzo, J.D.2, Majhail, N.S.11 1Abramson Cancer Center/U-
niversity of Pennsylvania, Philadelphia, PA; 2Center for International
Blood and Marrow Transplant Research, Medical College of Wisconsin,
Milwaukee, WI; 3Fred Hutchinson Cancer Research Center, Seattle,
WA; 4The Children’s Memorial Medical Center, Chicago, IL; 5Leeds
Teaching Hospital, Leeds, United Kingdom; 6Kantonsspital Basel, Basel,
Switzerland; 7Cincinnati Children’s Hospital Medical Center, OH;
8Cleveland Clinic Foundation, OH; 9Shands Hospital at the University
of Florida, Gainesville, FL; 10Hopital Saint Louis, Paris, France; 11Uni-
versity of Minnesota Medical Center, Minneapolis, MN
Preservation of fertility and the ability to bear children after HCT
can be an important positive influence on the quality of life of young
transplant survivors. We describe 182 pregnancies that were re-
ported to the CIBMTR between 2002 and 2007 among female
HCT recipients (N5 84) or partners of male HCT recipients
(N5 98). Transplant types included autologous (auto) HCT (20
women, 13 men), myeloablative (MA) allogeneic (allo) HCT (50
women, 80 men) and non-myeloablative (NMA) allo HCT (14
women, 5 men). Age at HCT was\10 years for 6% women and
4% men and 10-19 years for 44% women and 16% men. HCT
was performed for a non-malignant disorder in 58% women and
31% men. Conditioning regimen used total body irradiation (TBI)
in 16% women and 20% men. Bu-Cy conditioning was used in
6% women and 40% men. Six women and 6 men had received two
transplants before pregnancy. Fifteen men reported the use of cryo-
preserved sperm to facilitate pregnancy. Among 35 women who re-
ceived HCT for a malignant disorder, 4 had relapsed between HCT
and pregnancy; one was in remission and 3 had persistent disease at
time of pregnancy (Hodgkin’s lymphoma, myeloma and solid can-
cer). Among 66 men with malignant disorders, 12 had relapsed be-
tween HCT and pregnancy; of these 10 achieved a subsequent
remission and were disease free at the time of pregnancy. In sum-
mary, some HCT recipients can retain their fertility, including pa-
tients who have received myeloablative TBI based conditioning
and recipients of more than one HCT. Appropriate patients shouldPregnancy after HCT
Women
Variable Auto MA allo
N 20 54
Median age at HCT, range (yrs) 22 (16-33) 18 (5-45)
Median age at pregnancy, range (yrs) 28 (18-40) 28 (15-50)
Time b/w HCTand pregnancy
#5 years 7 (35%) 15 (28%)
.5 years 13 (65%) 39 (72%)
TBI in conditioning 0 10 (19%)
Median TBI dose (cGy) - 1200
Chronic GVHD - 12 (22%)
Received 2nd HCT* 0 4 ( 8%)
Median followup of survivors 9 yrs 11 yrs
*Two patients received three HCT’s.be counseled about fertility issues both before and after HCT. Out-
comes of pregnancy after HCT need prospective evaluation.59
SECOND SOLID CANCERS AFTER ALLOGENEIC HEMATOPOIETIC-CELL
TRANSPLANTATION USING BUSULFAN-CYCLOPHOSPHAMIDE CONDI-
TIONING
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5The Children’s Memorial Medical Center, Chicago, IL; 6Fred Hutchin-
son Cancer Research Center, Seattle,WA; 7ShandsHospital at the Univer-
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Survivors of allogeneic hematopoietic-cell transplantation (allo
HCT) who receive total body irradiation based conditioning
have 2 to 3 folds increased risks of developing second solid cancers
compared to the general population (Rizzo et al, Blood 2009). We
evaluated the risks of second solid cancers (excluding skin squa-
mous and basal cell cancers) in a population of allo HCT recipi-
ents who had received chemotherapy based conditioning. Our
study cohort consisted of 4349 pediatric and adult recipients of
allo HCT using busulfan-cyclophosphamide (Bu-Cy) conditioning
from 1986-2005 for acute myeloid leukemia in first complete re-
mission (AML CR1) or chronic myeloid leukemia in first chronic
phase (CML CP1). Patients with therapy related AML were ex-
cluded. The median followup of survivors was 8.2 years; 47%
had survived .5 years and 18% had survived .10 years after
HCT. Our cohort represented 22,269 person-years at risk. For
the whole cohort, 79% received HCT from HLA identical sib-
lings and 84% had bone marrow as graft source. Median age at
HCT was 29 years for AML and 36 years for CML. Acute (grade
2-4) and chronic graft-versus-host disease (GVHD) occurred in
34% and 33% of AML patients and 42% and 46% of CML pa-
tients, respectively. Sixty-six solid cancers were reported; the cu-
mulative incidence of solid cancers at 3, 5 and 10 years after
HCT was 0.7%, 0.9% and 2.0% for AML patients and 0.5%,
1.1% and 3.4% for CML patients. The overall rate of solid can-
cers among HCT recipients was significantly higher than the ex-
pected general population rates (observed to expected ratio [O/
E] 1.4; 95% confidence intervals 1.1-1.8). Significantly elevated
risks were observed for tumors of the lip (O/E 25.7), tongue
(O/E 9.1), mouth (O/E 7.2), esophagus (O/E 10.3), lung (O/E
2.6), soft tissue (O/E 7.1) and brain (O/E 4.7). On Cox-regression
analysis, older age at HCT, chronic GVHD and use of peripheral
blood as graft source increased the risks of solid cancers while use
of methotrexate (MTX) and cyclosporine (CSA) for GVHD pro-
phylaxis (vs. T-cell depletion) decreased the risks of solid cancers
(Table). Recipients of allo HCT for AML CR1 and CML CP1 us-
ing Bu-Cy conditioning are at risk of developing solid cancers,Men
NMA allo Auto MA allo NMA allo
10 13 81 3
24 (12-33) 28 (20-40) 24 (1-53) 34 (25-49)
26 (18-37) 32 (23-48) 31 (11-55) 35 (32-51)
8 (80%) 4 (31%) 25 (31%) 3 (100%)
2 (20%) 9 (69%) 56 (69%) 0
2 (20%) 1 ( 8%) 18 (22%) 1 (33%)
200 1320 1200 200
3 (30%) - 39 (48%) 2 (67%)
2 (14%) 2 (15%) 3 ( 4%) 1 (33%)
4 yrs 8 yrs 11 yrs 3 yrs
